Abstract
Methamphetamine is a drug that is significantly abused worldwide. Although long–lasting depletion of dopamine and other dopamine nerve terminal markers has been reported in striatum of nonhuman primates receiving very high doses of the psychostimulant1–3, no information is available for humans. We found reduced levels of three dopamine nerve terminal markers (dopamine, tyrosine hydroxylase and the dopamine transporter) in post–mortem striatum (nucleus accumbens, caudate, putamen) of chronic methamphetamine users. However, levels of DOPA decarboxylase and the vesicular monoamine transporter, known to be reduced in Parkinson's disease4,5, were normal. This suggests that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in our study. However, the dopamine reduction might explain some of the dysphoric effects of the drug, whereas the decreased dopamine transporter could provide the basis for dose escalation occurring in some methamphetamine users.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Seiden, L.S., Fishman, M.W. & Schuster, C.R. Long-term methamphetamine-induced changes in tolerant rhesus monkeys. Drug Alcohol Depend. 1, 215–219 (1976).
Preston, K.L., Wagner, G.C., Schuster, C.R. & Seiden, L.S. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res. 338, 243–248 (1985).
Woolverton, W.L., Ricaurte, G.A., Forno, L.S. & Seiden, L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486, 73–78 (1989).
Wilson, J.M. et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology (in the press).
Zhong, X.H. et al. Striatal tyrosine hydroxylase and dopa decarboxylase protein in dominantly-inherited olivopontocerebellar atrophy and idiopathic Parkinson's disease. Mov. Disord. 10, 10–17 (1995).
DiChiara, G. The role of dopamine in drug abuse reviewed from the perspective of its role in motivation. Drug Alcohol Depend. 38, 95–137 (1995).
Laruelle, M. et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36, 1182–1190 (1995).
Hartman, J.A. & Halaris, A.E. Compartmentation of catecholamines in rat brain: Effects of agonists and antagonists. Brain Res. 190, 421–436 (1980).
Kuczenski, R. Amphetamine-haloperidol interactions on striatal and mesolimbic tyrosine hydroxylase activity and dopamine metabolism. J. Pharmacol. Exp. Ther. 215, 135–142 (1980).
Chan, P. et al. Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 2484–2487 (1994).
Ricaurte, G.A., Schuster, C.R. & Seiden, L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res. 193, 153–163 (1980).
Ricaurte, G.A., Guillery, R.W., Seiden, L.S., Schuster, C.R. & Moore, R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93–103 (1982).
Brunswick, D.J., Benmansour, S., Tejani-Butt, S.M. & Hauptmann, M. Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse 11, 287–293 (1992).
O'Callaghan, J.P. & Miller, D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol Exp. Ther. 270, 741–751 (1994).
Miller, D.B. & O'Callaghan, J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 752–760 (1994).
Kish, S.J., Shannak, K. & Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318, 867–880 (1988).
DaSilva, J.N., Kilbourn, M.R. & Domino, E.F. In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET). Synapse 14, 128–131 (1993).
Giros, B. et al. Delineation of discrete domains for substrate, cocaine, and tri-cyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15985–15988 (1994).
Vaughan, R.A. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol. Pharmacol. 47, 956–964 (1994).
Wilson, J.M. et al. Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J. Neurosci. 14, 2966–2979 (1994).
Vander Borght, T.M., Kilbourn, M.R., Desmond, T.J., Kuhl, D.E. & Frey, K.A. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577–583 (1995).
Naudon, L., Leroux-Nicollet, I. & Costentin, J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci. Lett. 173, 1–4 (1994).
Wilson, J.M. & Kish, S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. (in the press).
Persico, A.M. et al. Dopaminergic gene expression during amphetamine withdrawal. NeuroReport 4, 41–44 (1993).
Robinson, T.E. & Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247–291 (1993).
Rossetti, Z.L., Hmaidan, Y. & Gessa, L. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221, 227–234 (1992).
Wise, R.A. & Munn, E. Withdrawal from chronic amphetamine elevates baseline intracranial self-administration thresholds. Psychopharmacology 117, 130–136 (1995).
Giros, B., Jaber, M., Jones, S.R., Wightman, R.M. & Caron, M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606–612 (1996).
Pifl, C., Drobny, H., Reither, H., Hornykiewicz, O. & Singer, E.A. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368–373 (1995).
Kuikka, J.T. et al. Altered serotonin and dopamine transporter densities associated with impulse violent behaviour. J. Nucl. Med. 36, 31P–32P (1995).
Fishbein, D.H., Lozovsky, D. & Jaffe, J.H. Impulsivity, aggression and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol. Psychiatry 25, 1049–1066 (1989).
Miczek, K.A. & Tidey, J.W. Amphetamines: Aggressive and social behavior. NIDA Res. Monogr. 94, 68–100 (1989).
Riley, H.A. An Atlas of the Basal Ganglia, Brainstem and Spinal Cord. (Hafner, New York, 1960).
Hörtnagl, H., Schlogl, E., Sperk, G. & Hornykiewicz, O. The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. Prog. Brain Res. 58, 269–274 (1983).
Ordway, G.A., Smith, K.S. & Haycock, J.W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem. 62, 680–685 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilson, J., Kalasinsky, K., Levey, A. et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2, 699–703 (1996). https://doi.org/10.1038/nm0696-699
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0696-699
This article is cited by
-
Dopamine dysfunction in stimulant use disorders: mechanistic comparisons and implications for treatment
Molecular Psychiatry (2022)
-
Sex differences in neurobehavioral consequences of methamphetamine exposure in adult mice
Psychopharmacology (2022)
-
Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson’s disease
Metabolic Brain Disease (2022)
-
Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson’s disease: involvement of anti-inflammatory response
Experimental Brain Research (2022)
-
Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome
Molecular Psychiatry (2021)